Fulhold Pharma

Fulhold Pharma’s Intellectual Property is a biological platform technology with a wide range of applications in human and animal health.

[2][3][4] According to financial media group, MoneyWeb, the trading suspension was due to "fallout from the investigations into companies with links to Belvedere Management.

[2] A regulatory investigation by the Guernsey Financial Services Commission (GFSC) downgraded these original accusations to technical administrative breaches and ended in 2017 without any action being taken.

[2] Fulhold Pharma's Intellectual Property is a biological molecule, CarboHydrate Derived Fulvic Acid (CHD-FA) and is manufactured as an ingredient in medications.

[8] Research into CHD-FA's broad-spectrum anti-microbial/anti-inflammatory agency on drug-resistant Gram positive, Gram negative, and fungal pathogens through ingestion and topical application includes: A 2015 company press release listed David Squire as chief executive officer and chairman and Stephen Leivers as founder and chief scientific officer.